STOCK TITAN

Odyssey Group - ODYY STOCK NEWS

Welcome to our dedicated page for Odyssey Group news (Ticker: ODYY), a resource for investors and traders seeking the latest updates and insights on Odyssey Group stock.

Overview

Odyssey Health Inc. (ODYY), formerly known as Odyssey Group International, Inc., is a medical company dedicated to developing life-enhancing solutions through innovative medical products and technologies. With a focus on pioneering clinical utility and technological advancements, the company operates at the intersection of medical devices and healthcare innovation, carving out a distinct niche in its competitive landscape.

Core Business and Operations

Odyssey Health is primarily engaged in the creation, acquisition, and development of specialized assets and intellectual property within the medical sector. The company follows a strategic methodology: acquiring distinctive assets, refining them through intensive R&D, and ultimately partnering with or divesting to entities where the monetization of these assets is maximized. This business model enables Odyssey Health to focus on projects with strong technological advantages and demonstrated clinical benefits, making it a noteworthy entity in the realm of innovative medical solutions.

Strategic Asset Development

Central to its mission is a disciplined approach to asset management. Odyssey Health identifies market opportunities where its products can address unmet medical needs. By leveraging advanced research and scientific innovation, the company develops a portfolio of medical technologies that offer significant advantages over traditional models. This approach not only enables efficient product development but also provides a scalable model for expanding its suite of medical devices and technologies over time.

Market Position and Competitive Environment

Operating in a competitive healthcare market, Odyssey Health stands out due to its clear focus on strategic asset acquisition and development. The company employs a methodical process, which includes identifying promising medical technologies, investing in their further development, and realizing value through strategic partnerships or divestitures. This model places the company in a favorable position relative to its peers, as it leverages innovation and clinical validations to carve out robust, sustainable market segments within the high-stakes arena of medical devices and health solutions.

Innovative Approach and Value Proposition

Odyssey Health emphasizes the value of technological advantage and clinically validated applications in its process. The company is known for its pragmatic approach to innovation, ensuring that all developed assets are backed by strong scientific rationale and a clear pathway to market viability. By focusing on areas that deliver superior clinical utility, Odyssey Health maintains a competitive edge that resonates with industry experts and investors alike.

Operational Highlights

  • Asset Acquisition: Identifying and acquiring valuable intellectual property and medical technologies with clear market potential.
  • Research and Development: Enhancing acquired assets through robust R&D initiatives to achieve technological differentiation.
  • Strategic Partnerships: Engaging with other industry players to monetize value and expand market reach.
  • Market Focus: Concentrating on products that offer meaningful, life-enhancing solutions and address significant clinical needs.

Industry Relevance

In the broader context of medical devices and healthcare, Odyssey Health is recognized for its commitment to merging clinical innovation with practical monetization strategies. The company’s approach facilitates the transition of groundbreaking technologies from the laboratory to real-world healthcare applications, ensuring that each product not only meets clinical standards but also captures market interest. This integration of innovation and commercialization forms the backbone of its operational strategy.

Conclusion

Overall, Odyssey Health Inc. represents a focused and strategic approach within the healthcare industry, dedicated to transforming innovative medical technologies into tangible, life-enhancing solutions. Its emphasis on select clinical areas, systematic asset development, and strategic partnerships underpins its role as a key player in the evolving landscape of medical devices and healthcare innovation.

Rhea-AI Summary
Odyssey Health, Inc. (ODYY) reports $13.2 million in net income and $8.7 million in total stockholder equity for the quarter ended January 31, 2024. The increase is attributed to the sale of neurological assets to Oragenics, Inc. The company received eight million shares of Oragenics Series F preferred stock, enhancing its balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
none
-
Rhea-AI Summary
Odyssey Health, Inc. (OTCQB:ODYY) announces the closing of an Asset Purchase Agreement with Oragenics, Inc. (OGEN:NYSE American) for the acquisition of Odyssey's proprietary assets related to its neurological drug therapy platform. The agreement includes cash payments, issuance of preferred stock, and collaboration for the development of drug candidates for treating concussion and Niemann Pick Disease Type C. Odyssey's lead drug candidate, ONP-002, has shown promising results in preclinical and Phase 1 human clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none
-
Rhea-AI Summary
Odyssey Health, Inc. (OTCOB:ODYY) received stockholder approval for the sale of its neurological drug platform technology to Oragenics, Inc. at a Special Meeting on December 7, 2023. The asset purchase agreement includes a $1,000,000 consideration, with $500,000 already received and an additional $500,000 payment upon the successful proxy vote. Odyssey will also receive eight million shares of Oragenics Convertible Preferred Class F stock. The transaction is expected to close before the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none
Rhea-AI Summary
Odyssey Health, Inc. (OTCQB:ODYY) selects Syneos Health® to support its Investigational New Drug (IND) Application for its lead drug candidate ONP-002, targeting mild Traumatic Brain Injury (mTBI). Syneos Health will provide guidance and review of pre-clinical and clinical data, as well as support for the Phase II clinical trial design in the US. The partnership aims to position the study for success by leveraging Syneos Health's expertise and regulatory affairs solutions (GRAS) for neurological drugs and intranasal devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
none
-
Rhea-AI Summary
Odyssey Health, Inc. (OTCQB:ODYY) will hold a webcast on November 16, 2023, to provide an update on the company, recap its progress, and discuss the sale of the neurological technology platform to Oragenics, Inc. Participants can join via web link or phone. The company will receive 8 million shares of Oragenics, Inc. Series F Preferred convertible stock as part of the asset purchase agreement. The Special Meeting related to the sale will be held on December 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
none
-
Rhea-AI Summary
Odyssey Health provides an update on its Asset Purchase Agreement with Oragenics
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.65%
Tags
none
Rhea-AI Summary
Oragenics to acquire Odyssey Health's assets related to neurological drug therapies and technologies, including drug candidates for treating mild traumatic brain injury and Niemann Pick Disease Type C, as well as a proprietary powder formulation and nasal delivery device. The transaction includes $1.0 million in cash payments and eight million shares of Oragenics' Series F Convertible Preferred Stock. The deal is expected to close in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.71%
Tags
-
Rhea-AI Summary
Odyssey Health, Inc. (OTCQB: ODYY) has commenced trading on the OTCQB Market after up-listing from the OTC Pink Market. The up-listing expands the audience of investors that can invest in the company. Odyssey is focused on developing nasal delivery of proprietary compounds to treat neurological disorders, including mTBI. The company aims to drive enhanced clinical efficacy from its products and create shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.86%
Tags
none
-
Rhea-AI Summary
Odyssey Health, Inc. presented at the Military Health System Research Symposium (MHSRS) on their novel pharmaceutical, ONP-002, for brain-targeted delivery in mild traumatic brain injury (mTBI). The poster included positive preclinical data and safety findings from Phase I clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.47%
Tags
none

FAQ

What is the current stock price of Odyssey Group (ODYY)?

The current stock price of Odyssey Group (ODYY) is $0.0087 as of April 10, 2025.

What is the market cap of Odyssey Group (ODYY)?

The market cap of Odyssey Group (ODYY) is approximately 967.1K.

What is the core business of Odyssey Health Inc.?

Odyssey Health Inc. is focused on developing life-enhancing medical solutions through the acquisition, development, and strategic monetization of innovative medical technologies.

How does Odyssey Health generate revenue?

The company generates revenue by acquiring specialized medical assets, investing in their research and development, and then partnering with or divesting these assets to realize their market value.

What distinguishes Odyssey Health's business model?

Odyssey Health employs a targeted asset development strategy that emphasizes technological advantage, clinical utility, and strategic partnerships, differentiating it from traditional medical device companies.

Which industry segments does Odyssey Health operate in?

The company is active in the medical devices and healthcare innovation sectors, with an emphasis on developing technologies that offer significant clinical benefits and improved patient outcomes.

What role does research and development play in the company's operations?

Research and development is central to Odyssey Health's strategy, enabling the refinement and advancement of acquired assets to ensure they meet high clinical and technological standards.

How does Odyssey Health maintain its competitive edge in the market?

By focusing on well-defined market opportunities and leveraging strategic asset acquisition and monetization, Odyssey Health ensures its innovations deliver superior clinical utility and market relevance.

How is Odyssey Health positioned within the OTC market?

Odyssey Health is listed on the OTC market, where its clear focus on medical innovation and asset development has enabled it to capture attention as a company committed to advancing healthcare solutions.

How do strategic partnerships factor into Odyssey Health's operations?

Strategic partnerships allow Odyssey Health to effectively monetize its developed assets, extend its market reach, and collaborate with other innovators in the healthcare space, enhancing its overall business impact.
Odyssey Group

OTC:ODYY

ODYY Rankings

ODYY Stock Data

967.10k
80.07M
17.2%
Medical Devices
Healthcare
Link
United States
Las Vegas